AbbVie (NYSE: ABBV) isn’t what it once was, a one-trick pony dependent on Humira. Today, AbbVie is a well-diversified business with numerous blockbusters. No longer dependent on a single product or segment, the company has nimbly moved past its patent cliff and is on track to sustain growth and, more importantly, cash flow, long into the future.
The takeaway for investors is that this stock not only pays a healthy dividend, with distribution increases expected, but is also on track for higher share prices too, with the potential to advance above $300 by year’s end.
